header image

Take a look through our annual reports.

How to contact us for media/press enquiries.

Have a comment or question? Get in touch.

News

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A

06-18-2018

Lachen, Switzerland 18 June 2018: Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII)...

Octapharma share promising preclinical data for SubQ-8, a novel subcutaneous recombinant FVIII, at WFH 2018

05-28-2018

Lachen, Switzerland 28 May 2018: Octapharma announced today that pre-clinical data for SubQ-8 were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK. SubQ-8,...

Octapharma present new data on the benefits of Nuwiq® in patients with haemophilia A at the World Federation of Hemophilia 2018 World Congress

05-28-2018

Lachen, Switzerland 28 May 2018: Octapharma announced today that new data on the benefits of Nuwiq® in patients with haemophilia A were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World...

Octapharma USA Funds Only National Camp Exchange Program for Bleeding Disorders Community Camps

05-09-2018

Interested Camp Professionals Should Apply by May 30th for Grant Funded Program

Chris Bombardier, First Hemophiliac to Climb the Seven Summits, Joins Octapharma USA at HFA Annual Symposium in Cleveland

04-26-2018

Mountain Climber Will Discuss Mount Everest Climb, Upcoming Documentary One-on-One With Visitors of Octapharma Booth

Octapharma USA Grant Supports National Conference for Type 3 von Willebrand Disease Patients

04-11-2018

‘Making the Connection’ will be held June 22 – 25 in Palm Beach Gardens, Florida

Octapharma Group publishes 2017 annual results reporting revenue of €1.72 billion and operating income of €349 million

03-01-2018

Lachen, Switzerland, March 1st, 2018: Over the last six years, the Octapharma Group has accomplished a remarkable compound annual growth rate of 15% and reports another record-breaking result for 2017, with sales of €1.72 billion...